Latest news with #Ibrutinib
Business Upturn
2 days ago
- Business
- Business Upturn
Stocks to watch on July 28: Titan, BEL, SAIL, Kotak Bank, TCS, Zydus, Brigade in focus after key deals and earnings
By Arunika Jain Published on July 28, 2025, 08:02 IST Several stocks are likely to be in focus on July 28 following major order wins, corporate developments, and quarterly earnings announcements. Here's a roundup of key newsmakers from the India Daybook: Major deals and project wins Titan Company announced the acquisition of Damas Jewellery, marking a strategic expansion in its international jewellery footprint. Bharat Electronics Ltd (BEL) secured a ₹1,640 crore defence contract for advanced air surveillance radars, while RITES bagged a ₹177 crore manufacturing unit project from BEL in Andhra Pradesh. Asian Energy Services received an ₹865 crore order from Vedanta, and Vatech Wabag secured a ₹380 crore water reuse project in Bengaluru. L&T Technology Services won a $60 million software engineering engagement from a Tier-I US telecom provider, and Nibe entered a technical collaboration with Israel's Elbit Systems for the PULS rocket system. Godrej Industries' aerospace unit signed a strategic manufacturing deal with Pratt & Whitney for supplying precision aircraft components. Zydus Lifesciences received tentative USFDA approval for a generic version of Ibrutinib tablets. Realty and infra updates Brigade Enterprises launched its premium residential project 'Brigade Avalon' in Whitefield, Bengaluru, with expected revenue of over ₹1,000 crore. Agi Infra will consider a stock split proposal on August 4, and Royal Orchid Hotels announced its fifth property in Mysore under the Regenta Resort Tropical Villages brand. NTPC Green signed an MoU with Bihar State Power Generation for renewable and battery storage projects, while Jayant Infratech won a ₹34 crore EPC contract for rail electrification in Assam. Positive earnings Several companies reported robust Q1 FY26 results: SAIL: Net profit at ₹744 crore vs ₹81.7 crore; revenue at ₹25,921 crore vs ₹23,997 crore (YoY). Lodha Developers: Net profit at ₹675 crore vs ₹475 crore; revenue at ₹3,492 crore vs ₹2,847 crore. Orient Cement: Net profit rose sharply to ₹201 crore vs ₹36.7 crore; revenue at ₹870 crore vs ₹701 crore. ACME: Net profit at ₹131 crore vs ₹1.4 crore; revenue at ₹511 crore vs ₹310 crore. Affle: Net profit at ₹105 crore vs ₹86 crore; revenue at ₹620 crore vs ₹519 crore. Premier Energies, Tata Chemicals, SG Mart, Schaeffler India and Omax Autos also posted strong YoY growth. Financial sector highlights Kotak Mahindra Bank reported Q1 net profit of ₹3,281.7 crore, slightly below estimates (poll: ₹3,442 crore). NII stood at ₹7,259.3 crore. Bank of Baroda exceeded expectations with net profit at ₹4,541 crore and NII at ₹11,435 crore. SBI Cards, IDFC First Bank, J&K Bank, TMB, Poonawalla Fincorp and Indian Overseas Bank also announced results, largely in line with estimates. Neutral to negative developments TCS announced plans to cut 2% of its global workforce over the course of FY26. Crisil was penalised ₹8 crore in a GST-related case on export services. Dr. Reddy's invested ₹565.4 crore in its Russia subsidiary, increasing its stake to 45.19%. On the earnings front, New Delhi Television Ltd (NDTV) reported a wider loss of ₹70.31 crore YoY, while CDSL, Petronet LNG, Zen Technologies, and Suraj Estate posted lower profits. Balkrishna Industries reported a steep decline in net profit to ₹288 crore from ₹490 crore, and Prataap Snacks saw its profit slump to ₹0.7 crore vs ₹9.4 crore YoY. CG Power received a ₹468 crore tax demand order from the Income Tax Department. Corporate and regulatory updates Menon Bearings declared an interim dividend of ₹2/share (record date: July 31). IndusInd Bank will appoint a new MD & CEO by August 28. Sona BLW clarified that former shareholder Rani Kapur hasn't held shares since 2019. Several stocks like Aurionpro , BASF , Wipro , CRISIL , and DLF are trading ex-dividend in the coming sessions. Changes in ASM and circuit filters: Datamatics, IEX, and Force Motors added to ASM; V2 Retail, Vadilal, and Magellanic excluded. Disclaimer: This article is based solely on publicly available company disclosures and stock exchange filings. It is not a recommendation to buy or sell any security. Please consult a qualified financial advisor before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
Business Standard
6 days ago
- Business
- Business Standard
Zydus receives USFDA tentative approval for Ibrutinib tablets
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg (USRLD: Imbruvica tablets, 140 mg, 280 mg and 420 mg). Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, and Waldenstrom's macroglobulinemia (WM). Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. Ibrutinib tablets had annual sales of USD 2148.9 mn in the United States (IQVIA MAT May 2025). The group now has 420 approvals and has so far filed 484 ANDAs since the commencement of the filing process in FY 2003-04.
Business Standard
6 days ago
- Business
- Business Standard
Zydus Lifesciences gets USFDA Nod for Ibrutinib tablets
Zydus Lifesciences informed that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg. Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) with a 17p deletion, and Waldenstr's macroglobulinemia (WM). Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. The tablets had annual sales of $2,148.9 million in the United States (IQVIA MAT May 2025). The group now holds 420 approvals and has filed a total of 484 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences rose 0.78% to currently trade at Rs 969.15 on the BSE.
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Zydus Lifesciences gets tentative USFDA nod for generic blood cancer drug
Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets. The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement. The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added. The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.
News18
6 days ago
- Business
- News18
Zydus Lifesciences gets tentative nod from USFDA for generic blood cancer drug
New Delhi, Jul 24 (PTI) Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets. The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement. The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added. The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US. PTI RKL DR DR Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
